NOV. 25th, 2020
Wound Care Plus, LLC Adopts the MolecuLight i:X® as a Standard Point-of-Care Device for its Wound Care Service Offering to the Long-Term Care and Extended Care Markets
Toronto, Canada and Midwest, USA – (December 10, 2020) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing bacteria, announced that Wound Care Plus, LLC, the largest mobile wound care provider in the US Midwest, has adopted the MolecuLight i:X point-of-care imaging device to be included as part of its standard of care services offered to the long-term care and extended care markets.
Long-term care (LTC) facilities have a disproportionately high rate of wounds and related infections1 compared to the general population. Skin and soft tissue infections are the third most common infection found in this care setting, with a high incidence rate of up to 2.1 cases/1000 resident days.2 Often, infections develop in these wounds due to delayed detection of high bacterial loads coupled with an immunocompromised population suppressing signs and symptoms of infection. Improving the detection of clinically significant levels of bacteria may limit the development of invasive or systemic infection in this vulnerable patient population.
“After a rigorous evaluation of our technology, we are thrilled to announce that Wound Care Plus, LLC has adopted the MolecuLight i:X as a standard-of-care to support their clients in long-term care and extended care facilities across 14 states”, says Anil Amlani, MolecuLight’s CEO. “This is yet another example of how the MolecuLight i:X device is complementing the clinical decision-making of wound care professionals – and ultimately helping to improve clinical outcomes within long-term care and extended care facilities”.